Insilico Medicine agreed to a deal that splits rights for a preclinical, brain‑penetrant NLRP3 inhibitor, securing a $10 million upfront from a newly formed Chinese biotech and setting up a broader $66 million transaction to allocate global rights. The agreement reflects rising industry interest in NLRP3 inflammasome inhibitors for neurodegenerative disease, positions Insilico to monetize AI‑driven discovery outputs, and signals growing Chinese investment in preclinical neuroscience assets.